Fuentes, FernandoGiménez, María JoséMarco, FrancescAlou Cervera, LuisAguilar, LorenzoPrieto Prieto, José2024-07-292024-07-292000-03-03Fuentes F, Giménez MJ, Marco F, Alou L, Aguilar L, Prieto J. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin. Eur J Clin Microbiol Infect Dis. 2000 Feb;19(2):137-9.0934-972310.1007/s100960050446https://hdl.handle.net/20.500.14352/107190The in vitro susceptibility to trovafloxacin and gemifloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin (MIC > or =2 microg/ml; 30 strains with intermediate resistance [MIC 2 microg/ml] and 43 strains with complete resistance [MIC > or =4 microg/ml]) was determined. Seventy-three strains collected in a surveillance study carried out from May 1996 to April 1997 in Spain (prior to commercialisation of trovafloxacin and gemifloxacin) from patients with respiratory tract infections were tested. The antibacterial activity of gemifloxacin was affected to a lesser extent than that of trovafloxacin by the increase in the MIC of ciprofloxacin, with gemifloxacin showing significantly (P< or =0.001) better antibacterial activity than trovafloxacin in all ciprofloxacin MIC categories (MIC50/MIC90 values of 0.015/0.03, 0.015/0.06, 0.03/0.06 and 0.12/0.25 microg/ml for gemifloxacin vs. 0.12/0.12, 0.12/1, 0.25/0.5 and 2/4 microg/ml for trovafloxacin in the 2, 4, 8 and > or =16 microg/ml ciprofloxacin MIC categories, respectively). Nine (12.3%) of these 73 strains exhibited decreased susceptibility to trovafloxacin (> or =2 microg/ml), whereas all strains were inhibited by 0.25 microg/ml of gemifloxacin.engjournal article1435-4373https://doi.org/10.1007/s100960050446https://link.springer.com/article/10.1007/s100960050446restricted access611.02Tract InfectionAntibacterial ActivityRespiratory TractRespiratory Tract InfectionStreptococcus PneumoniaeMicrobiología médica2414 Microbiología